Vertigo - Pipeline Insight, 2025

DelveInsight’s, “Vertigo - Pipeline Insight, 2025,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Vertigo pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Vertigo Understanding

Vertigo: Overview

Vertigo is a symptom, rather than a condition itself. It's the sensation that you, or the environment around you, is moving or spinning. This feeling may be barely noticeable, or it may be so severe that you find it difficult to keep your balance and do everyday tasks. Attacks of vertigo can develop suddenly and last for a few seconds, or they may last much longer. If a person have severe vertigo, the symptoms may be constant and last for several days, making normal life very difficult. Vertigo is commonly caused by a problem with the way balance works in the inner ear, although it can also be caused by problems in certain parts of the brain. Some cases of vertigo improve over time, without treatment. However, some people have repeated episodes for many months, or even years, such as those with Ménière's disease. There are specific treatments for some causes of vertigo. A series of simple head movements (known as the Epley manoeuvre) is used to treat BPPV. Medicines, such as prochlorperazine and some antihistamines, can help in the early stages or most cases of vertigo.

""Vertigo - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vertigo pipeline landscape is provided which includes the disease overview and Vertigo treatment guidelines. The assessment part of the report embraces, in depth Vertigo commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vertigo collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Vertigo R&D. The therapies under development are focused on novel approaches to treat/improve Vertigo.

Vertigo Emerging Drugs Chapters

This segment of the Vertigo report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vertigo Emerging Drugs

• AM-125: Auris Medical

Auris Medical is developing AM-125, an intranasal formulation of betahistine, for the treatment of vertigo. The intranasal delivery of AM-125 is intended to bypass the effects of first-pass metabolism found with oral delivery of betahistine. This is expected to offer significant additional benefits in terms of efficacy and tolerability. Betahistine is a small molecule drug that acts as a partial histamine H1-receptor agonist and a H3-receptor antagonist. The compound has demonstrated increased cochlear, vestibular and cerebral blood flow, vestibular compensation and the ability to inhibit neuronal firing in the vestibular nuclei. In the case of vertigo, the objective is to restore balance. AM-125 is currently in Phase II stage of development.

• Seliforant: Sensorion

Seliforant (formerly SENS-111) is the first representative candidate of the histamine type 4 receptor antagonist class to be tested for the symptomatic treatment of vertigo crises. Displaying a neuromodulation effect of the sensorineural inner ear cell function, Seliforant is a small molecule that can be taken orally or via a standard injection, and is currently in a separate Phase 2 clinical trial.

Further product details are provided in the report……..

Vertigo: Therapeutic Assessment

This segment of the report provides insights about the different Vertigo drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Vertigo

There are approx. 2+ key companies which are developing the therapies for Vertigo. The companies which have their Vertigo drug candidates in the most advanced stage, i.e. phase II include, Auris Medical.

• Phases

DelveInsight’s report covers around 2+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Vertigo pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vertigo: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vertigo therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vertigo drugs.

Vertigo Report Insights

• Vertigo Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Vertigo Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Vertigo drugs?
• How many Vertigo drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vertigo?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vertigo therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vertigo and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Auris Medical
• Sensorion
• Apsen Farmaceutica

Key Products

• AM-125
• Seliforant
• APSLXR

Show more